Replies to post #68467 on Biotech Values

[nivasvs]

<<Xarelto quiz (low-medium difficulty): Given that Xarelto has a long enough half-life for qD dosing, why are the only two doses being taken into the phase-3 trial in ACS 2.5mg and 5mg BID?>>

Dose related increase in bleeding that needs medical attention. 5 mg BID would provide similar plasma exposure of 10 mg QD dosing with reduced risk of bleeding.